Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is defined by the abundance of lipid droplets (LDs) in hepatocytes. While historically considered simply depots for energy storage, LDs are increasingly recognized to impact a wide range of biological processes that influence cellular metabolism, signaling, and function. While progress has been made toward understanding the factors leading to LD accumulation (i.e. steatosis) and its progression to advanced stages of NAFLD and/or systemic metabolic dysfunction, much remains to be resolved. SCOPE OF REVIEW: This review covers many facets of LD biology. We provide a brief overview of the major pathways of lipid accretion and degradation that contribute to steatosis and how they are altered in NAFLD. The major focus is on the relationship between LDs and cell function and the detailed mechanisms that couple or uncouple steatosis from the severity and progression of NAFLD and systemic comorbidities. The importance of specific lipids and proteins within or on LDs as key components that determine whether LD accumulation is linked to cellular and metabolic dysfunction is presented. We discuss emerging areas of LD biology and future research directions that are needed to advance our understanding of the role of LDs in NAFLD etiology. MAJOR CONCLUSIONS: Impairments in LD breakdown appear to contribute to disease progression, but inefficient incorporation of fatty acids (FAs) into LD-containing triacylglycerol (TAG) and the consequential changes in FA partitioning also affect NAFLD etiology. Increased LD abundance in hepatocytes does not necessarily equate to cellular dysfunction. While LD accumulation is the prerequisite step for most NAFLD cases, the protein and lipid composition of LDs are critical factors in determining the progression from simple steatosis. Further defining the detailed molecular mechanisms linking LDs to metabolic dysfunction is important for designing effective therapeutic approaches targeting NAFLD and its comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 3×
“Levels of PC, which is the principal phospholipid in the LD monolayer, are reduced in subjects with NAFLD and NASH, which suggests that alterations in the LD monolayer could also influence disease progression [130].”
BackgroundKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 1×
“The E167K mutant results in less TM6SF2 protein expression due to protein instability [189].”
BackgroundApplying systems-level spectral imaging and analysis to reveal the organelle interactome
Valm, A. M., Cohen, S., Legant, W. R., Melunis, J., Hershberg, U., Wait, E., Cohen, A. R., Davidson, M. W., Betzig, E., & Lippincott-Schwartz, J. (2017) · Nature · doi:10.1038/nature22369 · Cited by 1,113 · cited 1×
“Multispectral time-lapse imaging of six organelles simultaneously reveals nutrient-regulated LD interactions with the ER, mitochondria, lysosomes, Golgi, and peroxisomes [224], although interactions with other organelles also exist.”
BackgroundA Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 1×
“The rs72613567:TA allele results in a truncated and lower abundant protein associated with a reduction in numerous chronic liver diseases including NAFLD and non-alcoholic cirrhosis [174].”
BackgroundWilfling, F., Wang, H., Haas, J. T., Krahmer, N., Gould, T. J., Uchida, A., Cheng, J.-X., Graham, M., Christiano, R., Fröhlich, F., et al. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.01.013 · Cited by 806 · cited 1×
“The LD monolayer membrane contains numerous enzymes involved in TAG synthesis, such as acyl-CoA synthetases as well as the acyltransferases GPAT4 and DGAT2, which allow the expansion of preexisting LDs [28].”
Background
Cited by
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
A new perspective on NAFLD: Focusing on lipid droplets
Scorletti, E., & Carr, R. M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.009 · Cited by 373
Obese visceral fat tissue inflammation: from protective to detrimental?
Kolb, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02672-y · Cited by 353
Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Henderson, G. C. (2021) · Nutrients · doi:10.3390/nu13082590 · Cited by 152
Bórquez, J. C., Díaz-Castro, F., La Fuente, F. P.-D., Espinoza, K., Figueroa, A. M., Martínez-Ruíz, I., Hernández, V., López-Soldado, I., Ventura, R., Domingo, J. C., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2023.155765 · Cited by 54
Metadata
- Authors
- Mashek, D. G.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 50
- Pages
- 101115
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W3102906690
- Cited by
- 232
- References
- 41
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. https://app.cochat.ai/papers/10.1016/j.molmet.2020.101115
- The paper
- Mashek, D. G. (2021). Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2020.101115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.